$155.94
-0.72-0.46%
Ult. Agg.: Nov 6, 7:45 PM
Alnylam Pharmaceuticals (ALNY) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
| Trimestre fiscale | Data segnalata | EPS effettivo | EPS stimato | Sorpresa% |
|---|---|---|---|---|
| Q3 | Oct 29, 2026 | $16.26 | $2.09 | 678.0 % |
| Q2 | Jul 30, 2026 | $1.84 | $2.00 | -8.00 % |
| Q1 | Apr 30, 2026 | $1.99 | $1.36 | 46.3 % |
| Q4 | Feb 12, 2026 | $1.25 | $1.20 | 4.17 % |
Quarterly Revenue (Billions)
Alnylam Pharmaceuticals (ALNY) ha pubblicato l'ultima guidance il ottobre 29, 2026 per fiscal year 2026. La società ha previsto un fatturato pari a $5.28B - $5.72B per il periodo.
Rispetto alle previsioni precedenti, Alnylam Pharmaceuticals ha modificato le sue previsioni di fatturato da un intervallo precedente di .
Alnylam Pharmaceuticals ha pubblicato {{revenueDirection}} aggiornamenti delle previsioni tra il {{revenuePriorRange}} e il Alnylam Pharmaceuticals. 16
| Metric | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $2.09 | $2.00 | $1.36 | $1.20 |
| Actual | $16.26 | $1.84 | $1.99 | $1.25 |
| Surprise | +678.0% | -8.00% | +46.3% | +4.17% |
| Revenue | ||||
| Estimate | $1.43B | $1.32B | $1.12B | $1.15B |
| Actual | $1.46B | $1.29B | $1.17B | $1.10B |
| Surprise | +1.74% | -2.02% | +4.26% | -4.64% |
| Metric | Q4 '26E | Q1 '27E | Q2 '27E | Q3 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $2.20 | $2.53 | $1.98 | $2.14 |
| Revenue | ||||
| Consensus | $1.52B | $1.55B | — | — |
| Trimestre fiscale | Data segnalata | Entrate effettive | Entrate stimate | Sorpresa% |
|---|---|---|---|---|
| Q3 | Oct 29, 2026 | $1.46B | $1.43B | 1.74 % |
| Q2 | Jul 30, 2026 | $1.29B | $1.32B | -2.02 % |
| Q1 | Apr 30, 2026 | $1.17B | $1.12B | 4.26 % |
| Q4 | Feb 12, 2026 | $1.10B | $1.15B | -4.64 % |